Immunic to Participate in Investor Conferences in July NEW YORK, July 9, 2026 – Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor conferences in July: July 14-15: Leerink Partners Therapeutics Forum. E [ … ]

 Immunic to Participate in Investor, Industry and Scientific Conferences in June NEW YORK, June 10, 2026 – Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor, industry and scientific conferences in June: [ … ]

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis – Late-Breaking Poster Introduces New Unified Statistical Analyses for Assessing Confirmed Disability Changes for Trials in Progressive Multiple Sclerosis –  – Additional C [ … ]

Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update  – Appointed Globally Renowned Biopharmaceutical Executive and Neurology Drug Developer, Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer – – Continued to Execute Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis, with To [ … ]

Immunic to Participate in Investor and Medical Conferences in May NEW YORK, April 30, 2026 – Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor and medical conferences in May: May 4-6 and 12-13: 26th Bi [ … ]

Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer  – Proven Leader in Neurology Drug Development, Including for Several Approved Multiple Sclerosis Therapies –  – Strong Experience in Advancing Late-Stage Clinical Programs and Obtaining Global Regulatory Approvals, Key to Suppor [ … ]

Immunic Announces Grant of Key European PatentProtecting Relevant Dosing Regimens for Vidofludimus Calcium  – Patent Covers Label-Mandated Dosing Scheme Across All Indications, Including Multiple Sclerosis; Previously Granted by the USPTO in 2023 – – Broad Protection Extends to All Forms of Vidofludimus, Including Its Salts, Solvates and Free Aci [ … ]

Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update – Top-Line Data from Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Expected by Year-End 2026 –  – Raised Proceeds of $200 Million in a Private Placement, with Potential for up to an Additional $200 Million –  – Net Proceeds Expecte [ … ]